Acasti Announces Second Quarter 2024 Financial Results and Business Highlights
Acasti Announces Second Quarter 2024 Financial Results and Business Highlights
Acasti公布2024年第二季度财务业绩和业务亮点
- Announced Dosing of First Patient in Pivotal STRIVE-ON Phase 3 Randomized Trial for GTX-104
- Completed $7.5 Million Private Placement Equity Financing led by ADAR1 Partners, LP, Providing Funding Well Beyond Anticipated Submission of GTX-104 New Drug Application (NDA)
- Highlighted the Potential of GTX-104 as New Treatment Standard for Aneurysmal Subarachnoid Hemorrhage (aSAH) in Key Opinion Leader Virtual Webinar
- Presented Poster on Pharmacokinetic Comparison of GTX-104 with Oral Nimodipine at 2023 Neurocritical Care Society Annual Meeting
- 宣布在 GTX-104 的 Pivotal STRIVE-ON 第 3 期随机试验中首位患者给药
- 完成了由 ADAR1 Partners, LP 牵头的 750 万美元私募股权融资，提供的资金远远超出预期的 GTX-104 新药申请 (NDA) 提交量
- 强调了 GTX-104 作为动脉瘤蛛网膜下腔出血 (aSaH) 新治疗标准的潜力 在关键意见领袖虚拟网络研讨会中
- 在 2023 年神经重症监护学会年会上展示了 GTX-104 与口服尼莫地平药代动力学比较的海报